Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HFE siRNA is a small interfering RNA designed to silence the expression of the HFE (Homeostatic Iron Regulator) gene. HFE is a protein involved in iron metabolism, and its variants (such as C282Y) are associated with increased iron accumulation, which can promote oxidative stress and oncogenesis. Research conducted at the Penn State College of Medicine demonstrated that HFE is highly expressed in various brain tumors, including glioblastoma and neuroblastoma. In preclinical models, HFE siRNA treatment significantly inhibited the proliferation of cancer cells and reduced tumor growth in vivo, suggesting that HFE inhibition may be a viable therapeutic strategy for iron-dependent malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HFE siRNA.